Tumor necrosis factor receptor (TNFR) associated factor 4 (TRAF4) was initially identified as a gene amplified and overexpressed in breast carcinomas. Our aim was to evaluate whether TRAF4 protein overexpression exists in other cancer types. Immunohistochemistry analysis of tumor samples from 623 patients with 20 different tumor types showed that TRAF4 was overexpressed in 268 tumors (43%), including 82 of 137 lung adenocarcinomas (60%). Interestingly, 32 primary tumors and their matching metastases exhibited mostly similar TRAF4 expression pattern. TRAF4 protein overexpression was limited to cancer cells and the subcellular localization was consistently cytoplasmic in a large majority of cases. To investigate changes in TRAF4 gene copy number, 125 cases from six different types of carcinomas were also analysed by fluorescence in situ hybridization. Out of the 28 cases (22%) showing an increased TRAF4 gene copy number, 23 (82%) were overexpressing the protein. Thus, TRAF4 gene amplification is one of the mechanisms responsible for TRAF4 protein overexpression in human cancers. Considering that TRAF4 is located at 17q11.2 in a region of amplification devoid of known oncogenes and is commonly overexpressed in cancer, our data support an oncogenic role for TRAF4.
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Unlike other members of the TRAF family, the biological function of TRAF4 remains elusive. Several reports suggested that TRAF4 could be recruited to different TNFR and TLR signalling pathways (Krajewska et al., 1998; Ye et al., 1999; Esparza and Arch, 2004; Takeshita et al., 2005) , and in mitogen-activated protein kinase (MAPK) pathways (Xu et al., 2002; Abell and Johnson, 2005; Li et al., 2005) but in vivo evidence of such a role is still missing. Mice deficient for TRAF4 exhibit clear ontogenic defects affecting neural tube closure, tracheal formation and skeletal patterning, phenotypes that might be linked to abnormal cell migration (Regnier et al., 2002) .
TRAF4 was the first member of the TRAF protein family found upregulated in human carcinomas. Indeed, the TRAF4 cDNA was initially isolated from metastatic breast cancer Tomasetto et al., 1995) , where the TRAF4 gene was amplified, leading to overexpression of the gene product (Bieche et al., 1996) . Detailed analysis of the amplification pattern of five genes located on the long arm of the chromosome 17, including the ERBB2 oncogene (Slamon et al., 1989) , revealed the existence of at least two different regions of amplification in breast tumors (Bieche et al., 1996) . The first amplicon includes ERBB2 and is well-characterized (Kauraniemi et al., 2001) whereas the second amplicon, closer to the centromere, contains TRAF4. The existence of a distinct region of amplification at 17q11.2 containing TRAF4 was confirmed by detailed analysis of genetic changes along the long arm of chromosome 17 in breast carcinoma cell lines and biopsies (Kauraniemi et al., 2001; Pollack et al., 2002) .
While previous studies have measured TRAF4 gene expression at the level of transcription in breast carcinomas, we report here, the analysis of TRAF4 protein expression in a large series of human cancers. Among the 623 tissue sections from 20 different tumor types that were screened for the expression of TRAF4 using immunohistochemistry, 268 (43%) cases from 18 different origins showed overexpression and were considered TRAF4 positive. TRAF4 staining was detected in the cancer cells and not in the underlying stroma (Figure 1 ). TRAF4 protein overexpression was most commonly observed in epithelial tumors (48%), but also in 31% of melanomas, 21% of neurogenic tumors and 17% of lymphomas. However, it was not detected in insulinoma (seven cases) or in follicular lymphoma (seven cases). In epithelial tumors, TRAF4 was overexpressed in approximately 60% of lung, breast and ovarian, 44% of bladder and 28% of colon carcinomas (Table 1) . Among these cases, TRAF4 was strongly overexpressed (2 þ ) in 32% of breast (Figure 1b) , 24% of lung (Figure 1h ), 12% of ovary ( Figure 1d ) and 11% of colon adenocarcinomas ( Figure 1f ). Thus, TRAF4 protein overexpression is a common feature of several human cancers. In a meta-analysis of human cancer cDNA microarray studies, TRAF4 belongs to a common transcriptional profile of 67 genes that are universally activated in most cancer types (Rhodes et al., 2004) . In the latter report, TRAF4 mRNA is overexpressed in lung adenocarcinoma, small cell lung carcinoma, ovary, colon and prostate carcinomas, which is in agreement with our data. Unlike transcriptome analyses of cancer samples, which do not provide information regarding cellular origin and subcellular localization of individual gene products, our study demonstrates clearly that overexpression of TRAF4 protein is limited to cancer cells.
The subcellular localization of TRAF4 was restricted to the cytoplasm in 79% of the tumors examined and representative examples of cytoplasmic staining are shown in Figure 1b , d, f and h. This was expected from earlier studies on TRAF4 localization in normal adult tissues (Krajewska et al., 1998) , endothelial cells (Li et al., 2005) and cells transiently overexpressing TRAF4 (Krajewska et al., 1998; Glauner et al., 2002; Sax and ElDeiry, 2003) . However, 10% of all cases exhibited both nuclear and cytoplasmic labelling whereas 11% showed exclusively nuclear staining (Table 1 ). TRAF4 nuclear localization was reported previously in invasive breast carcinoma and further investigated in vitro by transient expression of GFP-tagged deletion mutants that predominantly localized to the nucleus in HeLa cells (Glauner et al., 2002) . As TRAF4 nuclear localization was not seen in normal tissues (Krajewska et al., 1998) , changes in TRAF4 protein subcellular localization could be specific of the tumoral context. From our current knowledge, the mechanism and biological consequence of this nuclear localization of TRAF4 remain unknown.
Association between TRAF4 overexpression and nodal status was investigated in colon and lung adenocarcinomas. Among the 108 primary colon adenocarcinomas, there was no significant difference in TRAF4 overexpression between node negative (16/62; 26%) and node positive (11/46; 24%) patients. Similarly, among 137 lung adenocarcinomas, no significant difference was found in the number of node negative (55/88; 63%) and node positive (27/49; 55%) cases stained positive for TRAF4.
TRAF4 expression pattern was also examined in primary tumors and metastases. First, among the 121 colon adenocarcinomas analysed in our series, 108 were primary tumors and 13 were unmatched lung-metastases of colon adenocarcinomas. The detailed analysis of TRAF4 overexpression in these two groups suggested that it was more frequently detected in visceral metastases (7/13; 54%) than in primary colon adenocarcinomas (27/108; 25%). However, this difference was limit of significance (Fisher's exact probability test, P ¼ 0.046). Second, both the primary tumor and the associated metastasis from the same patient were obtained in 32 cases (13 ovary peritoneal metastases, 11 lung, 4 colon and 4 breast lymph node metastases). In most of the cases (28/32; 88%), similar expression pattern of TRAF4 was observed in the primary tumor and the matching metastasis. The four discordant cases corresponded to either a loss or a gain of TRAF4 expression and were likely linked to tumor heterogeneity analysed by tissue microarrays. This suggests that TRAF4 upregulation is more likely gained at an early stage of tumorigenesis rather than being acquired during cancer progression. Accordingly, gene expression profiles of primary breast carcinomas have revealed that genetic changes in the primary tumors are generally retained in their matching metastasis (Perou et al., 2000; Weigelt et al., 2003) .
To decipher the mechanism for deregulated expression of TRAF4, we performed FISH analysis on TMA slides containing 125 TRAF4-positive and negative tumor samples from breast, ovary, lung, colon, pancreas and thyroid origins. As shown on Figure 1j and k, a maximum of 10 TRAF4 gene copies per tumor cell was seen. Homogenous spread of the TRAF4 probe was observed in interphase nuclei without cluster pattern. We found that the TRAF4 gene copy number is increased in some cases of all cancer types tested, except in thyroid carcinomas (Table 2) . Overall in 22% (28/125) of cases, a gain in TRAF4 gene copy was found and it was associated to protein overexpression in 82% (23/28). In particular, FISH analysis revealed that overrepresentation or amplification of the TRAF4 gene was associated with protein overexpression in pancreas (3/3; 100%), breast (2/2; 100%), lung (15/18; 83%), ovary (2/3; 67%) and colon (1/2; 50%) carcinoma samples (Table 2) . Among these 23 tumor samples with combined TRAF4 gene amplification and overexpression, 17 (74%) showed a strong TRAF4 immunostaining (2 þ ), which suggests that increased TRAF4 gene copy number is associated to higher level of TRAF4 protein expression. Aside from high levels of amplification of known oncogenes, genome-wide analysis of gene copy number alterations in cancer revealed that the majority of transcriptional variations are due to low level copy number changes (Hyman et al., 2002; Wolf et al., 2004) . In our study, the TRAF4 gain observed in 22% of all cases was moderate (up to 10 copies) but it was significantly associated with gene expression. The common criterion for designating a gene as a putative Amplification and overexpression of TRAF4 in cancer S Camilleri-Broët et al target of an amplicon is that amplification leads to its overexpression (Collins et al., 1998) . We show that amplification represents one of the mechanisms leading to overexpression of the TRAF4 protein in most cancer types tested. Our findings are therefore in good agreement with the hypothesis that TRAF4 is a target of a distinct amplification region at 17q11.
Amplification of the TRAF4 and ERBB2 genes was analysed in parallel in 31 samples of primary lung adenocarcinomas, using a chromosome 17 centromeric probe as control. Overall, TRAF4 gain was found in 11/31 (35%) and ERBB2 in 6/31 (19%) tumor samples. Six out of the 11 cases with TRAF4 gain had no gain of ERBB2 and/or CEN17 (Figure 2 ). In the five remaining cases, a larger chromosomal region was involved, including both TRAF4 and ERBB2 genes. Among them, two cases showed a genetic gain of TRAF4, ERBB2 and CEN17, reflecting increased copy number of Amplification and overexpression of TRAF4 in cancer S Camilleri-Broët et al chromosome 17 (Figure 2 ). This indicates that TRAF4 gene amplification can occur independently of ERBB2 gain in lung carcinomas. Amplification at 17q has been extensively investigated in breast cancer (Orsetti et al., 2004) . However, genetic gains of chromosome 17q have also been reported in lung adenocarcinomas but the nature of the genes concerned by this genetic alteration remains poorly investigated (Balsara and Testa, 2002) . ERBB2 is expressed in about 30% of Non-Small Cell Lung Carcinomas (NSCLC), especially adenocarcinomas, although gene amplification is not usually the underlying mechanism (Hirsch et al., 2002) . In our analysis, TRAF4 overexpression was most commonly detected in this cancer type with 60% of lung adenocarcinomas concerned and it is due to gene amplification in about 38% of the cases. Interestingly, TRAF4 is found amplified independently of ERBB2 in more than half of these cases. Our data emphasize that TRAF4 represents a novel common target of deregulation in lung cancer. The May 2004 (hg17) human genome assembly was analysed with the UCSC Genome Browser (http:// genome.ucsc.edu/) to identify the genes contained in the 178 kb insert of the BAC clone RP11-386F9 used for FISH analysis. This BAC clone harbors seven transcribed genes localized in the 17q11.2 sub-band. Among these genes, only SDF2, NEK8 and TRAF4 have been found upregulated at the mRNA level in breast cancer TRAF4 immunostaining was considered negative when less than 5% of tumoral cells were stained, 1+ when TRAF4 was faintly or heterogeneously expressed in the cytoplasm in less than 50% of tumor cells and/or in the nucleus, and 2+ when TRAF4 was brightly expressed in the cytoplasm in more than 50% of tumor cells. Nuclear staining and cytoplasmic score 1+ and 2+ were considered overexpressed. Numbers of cases studied are indicated. %: percentage of TRAF4 positive cases per tumor type.
Figure 1 TRAF4 is overexpressed and amplified in human cancers. TRAF4 immunohistochemical staining in breast (a, b), ovary (c, d), colon (e, f) and lung (g, h) adenocarcinomas was homogeneous throughout each tumor sample and detects cytoplasmic overexpression in the four different types of cancer (b, d, f and h) ( Â 40 magnification). The anti-TRAF4 monoclonal antibody 5MLN-2H1 was previously described (Regnier et al., 2002) . The conditions for detecting TRAF4 above the basal level of expression were assessed using serial antibody dilutions on paraffin sections of HEK 293 cells stably overexpressing TRAF4 versus sections of wild-type cells. Using a 1:200 dilution, the TRAF4-transfected HEK 293 cells showed a cytoplasmic labeling in 80% of cells whereas no staining was seen in control cells (data not shown). Immunohistochemical analysis was performed retrospectively either on conventional slides or on TMA sections for 623 formalin-fixed, paraffin-embedded tissues, including 496 cases of epithelial tumors (452 primary tumors, 31 lymph node metastases of lung cancer and 13 colon derived lung metastases) from the department of Pathology, Hoˆtel-Dieu Hospital, Paris. After antigen retrieval (Target Retrieval Solution pH 9.9, DakoCytomation), 3 mm sections were incubated with the anti-TRAF4 antibody (1:200). The immunoreactivity was revealed with a commercially available streptavidin-biotin-peroxidase kit (Abcys). FISH analysis done on interphase nuclei of breast (i, j) and lung (k) adenocarcinomas shows 17q11.2 amplification (j, k). The methylrhodamine-labeled probe was generated from the chromosomal region that contains TRAF4 (BAC clone RP11-386F9) using the nick translation kit (Roche Diagnostics) and FISH was performed on TMA slides. Signal was visualized under a fluorescent microscope (Olympus BX41) at Â 1000 magnification.
tissues. Both SDF2 and TRAF4 showed a link between gene amplification and mRNA overexpression in breast tumors (Pollack et al., 2002) . NEK8 is the direct neighbor of the TRAF4 gene at 17q11.2 and was reported overexpressed at the mRNA level in breast tumors (Bowers and Boylan, 2004) . Considering the nature of gene amplification, SDF2 and NEK8 are likely to be co-amplified with TRAF4 in other cancer types. However, they were not reported in the meta-analysis as commonly upregulated in human cancers (Rhodes et al., 2004) . This suggests that TRAF4 represents the best candidate driver gene of the amplification at 17q11. To date, TRAF4 is the first TRAF protein known to be amplified and/or overexpressed in a wide-range of human malignancies. Overexpression of TRAF4 protein is the consequence of its gene amplification in about a quarter of human carcinomas. As occurs for established oncogenes such as ERBB2 and MYC, alternative mechanisms to increase TRAF4 expression also exist since 69% of the tumors examined overexpressed TRAF4 without alteration of the gene copy number. Although evidence for a direct oncogenic role of TRAF4 has yet to emerge, our results indicate that this protein is likely to play an important role in carcinogenesis. A very recent report shows that TRAF4 participates in endothelial cell migration within focal complexes (Wu et al., 2005) . Considering the importance of cell migration in cancer, we could hypothesize that TRAF4 upregulation could participate in and/or promote tumorigenesis. Fluorescence in situ hybridization revealed TRAF4 amplification (FISH+) or no change in copy number (FISHÀ). Immunohistochemistry was scored positive (IHC+) or negative (IHCÀ) for TRAF4 overexpression. Numbers of cases studied are indicated. The correlation between TRAF4 amplification and overexpression is statistically significant (Pearson's chi-square, P ¼ 0.005, n ¼ 125).
